Medivation Inc. (Nasdaq: MDVN) swung to an unexpected profit for the fourth quarter of 3 cents per diluted share compared with a loss of 43 cents per diluted share last year but the biopharmaceutical forecast 2014 revenue well below expectations prompting a downgrade. The stock price plummeted $12.61 to close at $71.91.
Medivation's Forecast Falls Far Short
February 28, 2014 at 16:33 PM EST
